Safety and Tolerability of FCM vs Standard of Care in Treating Iron Deficiency Anemia in Chronic Kidney Disease Patients

Status:
Completed

Trial end date:
2009-07-01

Target enrollment:

Participant gender:

The Objective of this study is to study the safety of FCM in patients with anemia caused by chronic kidney failure

Phase 3

American Regent, Inc.
Luitpold Pharmaceuticals

Ferric Compounds